Antifungal Activity of Anethum Graveolens Extract and Atrovastatin against Candida Species Compared to Fluconazole

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Mycology and Parasitology AND Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Mycology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Department of Pharmacology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan Iran

Abstract

Background: Candidiasis is one of the most important fungal infections caused by different species of Candida. The most common etiologic agent is Candida albicans. In recent years, there are many reports about the failure treatment of patients with different clinical forms of candidiasis. Statins have been found to have antifungal activity as well as cholesterol-lowering effects. Anethum graveolens has also exhibited antifungal and anti-hyperlipidemic activities. The purpose of the present study was evaluation of antifungal activity of Anethum graveolens and atrovastatin against Candida species in comparison with fluconazole.Methods: The present study was performed on 10 previously identified Candida isolates. Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) results were obtained and compared using microdilution method for fluconazole, atrovastatin and Anethum graveolens extract.Findings: Of 10 Candida isolates, 5 (50%) were susceptible to fluconazole and 3 (30%) were dose-dependent. Two isolates, including Candida albicans and Candida krusei, were resistant to fluconazole. MIC range for atrovastatin was 32-128 µg/ml.Conclusion: In this study, our finding showed that atrovastatin has antifungal activity as the same previous reports; but, aqueous extract of Anethum graveolens showed no antifungal activity against the Candida species (Candida albicans, Candida parapsilosis, Candida krusei, Candida glabrata, and Candida kefyr). 

Keywords


  1. Anaissie EJ, McGinnis MR, Pfaller MA. Clinical mycology. 1st ed. New York, NY: Churchill Livingstone; 2003.
  2. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46(6): 1704-13.
  3. Dassanayake RS, Ellepola AN, Samaranayake YH, Samaranayak LP. Molecular heterogeneity of fluconazole-resistant and -susceptible oral Candida albicans isolates within a single geographic locale. APMIS 2002; 110(4): 315-24.
  4. Westermeyer C, Macreadie IG. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res 2007; 7(3): 436-41.
  5. Forrest GN, Kopack AM, Perencevich EN. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect Dis 2010; 10: 152.
  6. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 2006; 262(1): 9-13.
  7. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
  8. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169(18): 1658-67.
  9. del RG, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200(4): 541-7.
  10. Evans WC. Trease and Evans' pharmacognosy. 16th ed. Philadelphia, PA: Saunders; 2009. p. 45, 264, 460, 503.
  11. Martindale W, Royal Pharmaceutical Society. The extra pharmacopoeia. 34th ed. London, UK: The Pharmaceutical Press; 2005. p. 300-10.
  12. Segen JC. Dictionary of alternative medicine. New York, NY; Appleton and Lange; 1998. p. 113.
  13. Hosseinzadeh H, Karimi GR, Ameri M. Effects of Anethum graveolens L. seed extracts on experimental gastric irritation models in mice. BMC Pharmacol 2002; 2: 21.
  14. Jirovetz L, Buchbauer G, Stoyanova AS, Georgiev EV, Damianova ST. Composition, quality control, and antimicrobial activity of the essential oil of long-time stored dill (Anethum graveolens L.) seeds from Bulgaria. J Agric Food Chem 2003; 51(13): 3854-7.
  15. Delaquis PJ, Stanich K, Girard B, Mazza G. Antimicrobial activity of individual and mixed fractions of dill, cilantro, coriander and eucalyptus essential oils. Int J Food Microbiol 2002; 74(1-2): 101-9.
  16. McGeady P, Wansley DL, Logan DA. Carvone and perillaldehyde interfere with the serum-induced formation of filamentous structures in Candida albicans at substantially lower concentrations than those causing significant inhibition of growth. J Nat Prod 2002; 65(7): 953-5.
  17. Clinical and Laboratory Standards Institute. CLSI document M27-A3. Wayne, PA: CLSI; 2008.
  18. Neppelenbroek KH, Campanha NH, Spolidorio DM, Spolidorio LC, Seo RS, Pavarina AC. Molecular fingerprinting methods for the discrimination between C. albicans and C. dubliniensis. Oral Dis 2006; 12(3): 242-53.
  19. Zeini F, Mehbod A, Emami M. Comprehensive medical mycology. Tehran, Iran: University of Tehran Press; 2009. [In Persian].
  20. Groll AH. Invasive opportunistic mycoses: clinical trials review, 2007-2008. Curr Infect Dis Rep 2008; 10(6): 451-3.
  21. Nosanchuk JD. Current status and future of antifungal therapy for systemic mycoses. Recent Pat Antiinfect Drug Discov 2006; 1(1): 75-84.
  22. Afeltra J, Verweij PE. Antifungal activity of nonantifungal drugs. Eur J Clin Microbiol Infect Dis 2003; 22(7): 397-407.
  23. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 2007; 44(8): 1089-90.
  24. Nyilasi I, Kocsube S, Pesti M, Lukacs G, Papp T, Vagvolgyi C. In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J Med Microbiol 2010; 59(Pt 2): 200-5.
  25. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50(1): 96-103.
  26. Menezes EA, Vasconcelos Junior AA, Silva CL, Plutarco FX, Cunha MC, Cunha FA. In vitro synergism of simvastatin and fluconazole against Candida species. Rev Inst Med Trop Sao Paulo 2012; 54(4): 197-9.
  27. Nyilasi I, Kocsube S, Galgَczy L, Papp T, Pesti M, Vagvِlgyi C. Effect of different statins on the antifungal activity of polyene antimycotics. Acta Biol Szeged 2010; 54(1): 33-6.
  28. Nyilasi I, Kocsube S, Krizsan K, Galgoczy L, Pesti M, Papp T, et al. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol Lett 2010; 307(2): 175-84.
  29. Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 2002; 51(2): 105-9.
  30. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis 2006; 6(4): 242-8.
  31. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008; 61(4): 774-85.
  32. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008; 61(4): 774-85.
  33. Liu G, Vellucci VF, Kyc S, Hostetter MK. Simvastatin inhibits Candida albicans biofilm in vitro. Pediatr Res 2009; 66(6): 600-4.
  34. Zeng H, Tian J, Zheng Y, Ban X, Zeng J, Mao Y, et al. In Vitro and In Vivo Activities of Essential Oil from the Seed of Anethum graveolens L. against Candida spp. Evid Based Complement Alternat Med 2011; 2011: 659704.
  35. Dadashpour M, Rasouli I, Seffidkon F, Taghizadeh M, Darvish AAS. Antimicrobial, antioxidant and cytotoxic properties of essential oil of Anethum graveolens L. Iranian Journal of Medicinal and Aromatic Plants 2013; 29(1): 63-73. [In Persian].
  36. Lopez P, Sanchez C, Batlle R, Nerin C. Solid- and vapor-phase antimicrobial activities of six essential oils: susceptibility of selected foodborne bacterial and fungal strains. J Agric Food Chem 2005; 53(17): 6939-46.
  37. Kaur GJ, Arora DS. Bioactive potential of Anethum graveolens, Foeniculum vulgare and Trachyspermum ammi belonging to the family Umbelliferae-Current status. J Med Plants Res 2010; 4(2): 87-94.